TY - JOUR T1 - Elevation of Circulating LIGHT (TNFSF14) and Interleukin-18 Levels in Sepsis-Induced Multi-Organ Injuries JF - medRxiv DO - 10.1101/2021.05.25.21257799 SP - 2021.05.25.21257799 AU - Hui-Qi Qu AU - Jingchun Qu AU - Thomas Dunn AU - James Snyder AU - Todd A. Miano AU - John Connolly AU - Joseph Glessner AU - Brian J. Anderson AU - John P. Reilly AU - Tiffanie K. Jones AU - Heather M. Giannini AU - Roseline S. Agyekum AU - Ariel R. Weisman AU - Caroline A.G. Ittner AU - Laura G. Rodrigues AU - Charlly Kao AU - Michael G.S. Shashaty AU - Patrick Sleiman AU - Nuala J. Meyer AU - Hakon Hakonarson Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/27/2021.05.25.21257799.abstract N2 - Objective The cytokines, LIGHT (TNFSF14) and Interleukin-18 (IL-18), are two important therapeutic targets due to their central roles in the function of activated T cells and inflammatory injury. LIGHT was recently shown to play a major role in COVID19 induced acute respiratory distress syndrome (ARDS), reducing mortality and hospital stay. This study aims to investigate the associations of LIGHT and IL-18 with non-COVID19 related ARDS, acute hypoxic respiratory failure (AHRF) or acute kidney injury (AKI), secondary to viral or bacterial sepsis.Research Design and Methods A cohort of 280 subjects diagnosed with sepsis, including 91 cases with sepsis triggered by viral infections, were investigated in this study and compared to healthy controls. Serum LIGHT, IL-18, and 59 other biomarkers (cytokines, chemokines and acute-phase reactants) were measured and associated with symptom severity.Results ARDS was observed in 36% of the patients, with 29% of the total patient cohort developing multi-organ failure (failure of two or more organs). We observed significantly increased LIGHT level (>2SD above mean of healthy subjects) in both bacterial sepsis patients (P=1.80E-05) and patients with sepsis from viral infections (P=1.78E-03). In bacterial sepsis, increased LIGHT level associated with ARDS, AKI and higher Apache III scores, findings also supported by correlations of LIGHT with other biomarkers of organ failures, suggesting LIGHT may be an inflammatory driver. IL-18 levels were highly variable across individuals, and consistently correlated with Apache III scores, mortality, and AKI, in both bacterial and viral sepsis.Conclusions For the first time, we demonstrate independent effects of LIGHT and IL-18 in septic organ failures. LIGHT levels are significantly elevated in non-COVID19 sepsis patients with ARDS and/or multi-organ failures suggesting that anti-LIGHT therapy may be effective therapy in a subset of patients with sepsis. Given the large variance of plasma IL-18 among septic subjects, targeting this pathway raises opportunities that require a precision application.Competing Interest StatementDr. Hakonarson and CHOP own stock in Cerecor. Drs. Meyer and Reilly are or have been site investigators for ARDS and sepsis clinical trials unrelated to the present work (sponsored by Quantum Leap Healthcare Collaborative; Athersys, Inc; Biomarck, Inc; and the Marcus Foundation). The authors declare no other potential conflicts of interest with respect to the research, authorship, and/or publication of this article.Funding StatementThe study was supported by: UPENN funding: The sepsis cohort study is supported by NIH HL137006 and HL137915 (Meyer). Cerecor funding: Sponsored research by Cerecor funded LIGHT and other biomarker measures. CHOP funding: Institutional Development Funds from the Childrens Hospital of Philadelphia to the Center for Applied Genomics, The Childrens Hospital of Philadelphia Endowed Chair in Genomic Research (HH). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Pennsylvania Institutional Review Board (IRB), protocol #808542. All human subjects or their proxies provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request. ER -